(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/024646 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 47/68 (2017.01) *C07K 16/30* (2006.01)

(21) International Application Number:
PCT/US2024/039521

(22) International Filing Date:
25 July 2024 (25.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2023/109322
26 July 2023 (26.07.2023) CN

(71) Applicant: **LYVGEN BIOPHARMA HOLDINGS LIMITED** [GB/—]; P.O. Box 31119, Grand Cayman, KY11-1205 (KY).

(72) Inventor; and
(71) Applicant: **WANG, Jieyi** [US/US]; 2317 Hastings Drive, Belmont, California 94002 (US).

(72) Inventors: **WU, Yi**; Building #4, 67 Li Bing Road, Pudong Zhangjiang Hi-Tech Park, Shanghai, Shanghai 201203 (CN). **LIU, Luyan**; Building #4, 67 Li Bing Road, Pudong Zhangjiang Hi-Tech Park, Shanghai, Shanghai 201203 (CN).

(74) Agent: **CHEN, Yahua**; c/o Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MULTI-SPECIFIC ANTIBODIES INTEGRATING DUAL IMMUNE MODULATING MOIETIES AND USES THEREOF IN IMMUNOTHERAPY

(57) Abstract: Multi-specific antibodies comprising a first Fv fragment targeting CD3, a second Fv fragment targeting an immune receptor such as CD137 or PD-L1, and one or more binding moieties targeting tumor associated antigens. Also provided herein are therapeutic uses of the multi-specific antibodies in cancer therapy.



FIG. 1B

WO 2025/024646 A1

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*